

**9.1 Lungenkarzinom****9.1.1 Staging****9.1.1.1 Qualität des Stagings mittels PET-CT und MRT-Schädel**

Heineman DJ, ten Berge MG, Daniels JM et al. The quality of Staging Non-Small Cell Lung Cancer in the Netherlands: Data from the Dutch lung Surgery Audit, *Ann Thorac Surg* 2016;102:1622-9.

Vernon J, Andruszkiewicz N, Schneider L et al. Comprehensive clinical Staging for Resectable Lung Cancer, Clinicopathological Correlations and the role for Brain MRI, *J Thorac Oncol* Vol,11 No.11;1970-1975.

**9.1.1.2 Mediastinales Staging vor stereotaktischer Bestrahlung**

Vial MR, Khan KA, O'Connell O, et al. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients, *Ann Thorac Surg* 2017;103:1600-6.

Czarnecka-Kujawa K, Rochau U, Siebert U et al. Cost-effectiveness of mediastinal lymph node staging in non-small cell lung cancer, *J Thorac Cardiovasc Surg* 2017;153:1576-78.

**9.1.2 Therapieoptionen Stadium I-II****9.1.2.1 Operative und nicht operative Verfahren****9.1.2.1.1 Atypische (Wedge)-Resektion versus stereotaktische Therapie bei Stadium IA nicht kleinzelliges Lungenkarzinom**

Yerokun BA, Yang CFJ, Gulack BC, et al. A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer, *J Thorac Cardiovasc Surg* 2017;154:675-86.

**9.1.2.1.2 Ergebnisse der stereotaktischen Strahlentherapie**

Woody NM, Stephans KL, Andrews M, et al. A Histologic Basis for the Efficacy of SBRT to the lung, *J Thorac Oncol* Vol 12 No.3;510-519.

Tekatli H, van't Hof S, Nossent EJ, et al. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm, *J Thorac Oncol* Vol ■ No. ■: ■-■.

Klapper AJ, Hittinger SA Denlinger CE, Alternatives to Lobectomy for High-Risk Patients with Early-Stage Non-Small Cell Lung Cancer, *Ann Thorac Surg* 2017;103:1330-9.

**9.1.2.2 Induktionschemotherapie bei cN1?**

Speicher PJ, Fitch ZW, Gulack BC et al. Induction Chemotherapy is not superior to a Surgery-first Strategy for Clinical N1 Non-Small Cell Lung Cancer, *Ann Thorac Surg* 2016;102:884-94.

**9.1.3 Therapieoptionen Stadium III****9.1.3.1 Op-Zeitpunkt bei multimodaler Therapie**

Gao SJ, Corso CD, Wang EH, et al. Timing of Surgery after Neoadjuvant Chemoradiation in locally advanced non-small Cell Lung Cancer, *J Thorac Oncol* Vol. 12 No. 2:314-322.

Samson P, Crabtree TD, Robinson CG et al. Defining the ideal Time Interval between planned Induction Therapy and Surgery for Stage IIIA non-small Cell Lung Cancer, *Ann Thorac Surg* 2017; ■:■-■.

### **9.1.3.2 Definitive Radiochemotherapie versus multimodale Therapie mit Operation mit Stadium III**

Pöttgen C, Eberhardt W, Stamatidis G et al. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) – a cumulative meta-analysis of the randomized evidence, *impactjournals.com/oncotarget* 2017.

### **9.1.4 Therapieoptionen Stadium IV (oligometastatisch)**

#### **9.1.4.1 Bedeutung des Lymphknotenstatus bei Oligometastasierung**

Johnson KK, Rosen JE, Salazar MC et al. Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer, *Ann thorac Surg* 2016;201:1166-71.

#### **9.1.4.2 Behandlungsergebnisse bei isoliertem Befall der Nebenniere**

Gao CL, Zhang KW, Tang MB, et al. Pooled analysis for surgical treatment for isolated adrenal metastasis and non-small cell lung cancer, *Interact CardioVasc Thorac Surg* 2017;24:1-7.

#### **9.1.4.3 Aggressive Lokalthherapie nach erfolgreicher first-line-Chemotherapie**

Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study, *Lancet Oncol* 2016;17:1672-82.

Kim C, Hoang CD, Kesarwala AH, et al. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer, *J Thorac Oncol* Vol.12 No.2:179-193.

### **9.1.5 Op-Techniken**

#### **9.1.5.1 VATS-Lobektomie versus offener Thorakotomie**

##### **9.1.5.1.1 Postoperative Schmerzen und Lebensqualität**

Bendixen M, Jorgensen OD, Kronborg C, et al. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer. a randomized controlled trial, *Lancet Oncol* 2016;17:836-44.

Salati M, Brunelli A, Xiume F, et al. Video-assisted thoracic surgery lobectomy does not offer any functional recovery advantage in comparison to the open approach 3 month after the operation: a case matched analysis, *Eur J of Cardiothorac Surg* 2017;51:1177-82.

##### **9.1.5.1.2 Bei kompromittierter Lungenfunktion**

Zang R, Ferguson MK, Video-Assisted versus Open Lobectomy in Patients with Compromised Lung Function: A Literature Review and Meta-Analysis, *PLoS ONE* 10(7):e0124512.

##### **9.1.5.1.3 Lymphadenektomie**

Zhang W, Wei Y, Jiang H, et al. Video-assisted thoracoscopic Surgery versus Thoracotomy Lymph Node Dissection in clinical Stage I Lung Cancer: A Meta-Analysis and System Review, *Ann Thorax Surg* 2016;

■:■-■.

#### **9.1.5.2 Uniportale versus multiportale VATS**

Perna V, Carvajal AF, Torrecilla JA, et al. Uniportal video-assisted thoracoscopic lobectomy versus other video-assisted thoracoscopic lobectomy techniques: a randomized study, *Eur J Cardiothorac Surg* 2016;50:411-5.

Hernandez-Arenas LA, Lin L, Yang Y, et al. Initial experience in uniportal subxiphoid video-assisted thoracoscopic surgery for major lung resections, *Eur J Cardiothorac Surg* 2016;50:1060-6.

**9.1.5.3 Thoraxchirurgische Eingriffe unter veno-venöser extrakorporaler Lungenunterstützung**

Redwan B, Ziegeler S, Freermann S, et al. Intraoperative veno-venous extracorporeal lung support in thoracic surgery: a single-centre experience, *Interact CardioVasc Thorac Surg* 2015;21:766-72.

**9.1.5.4 Zwerfellplikation bei akzidentieller oder geplanter Phrenicusresektion**

Beattie GW, Dunn WG, Asif M, In patients with a tumour invading the phrenic nerve does prophylactic diaphragm plication improve postoperative lung function? *Interact CardioVasc Thorac Surg* 2016;23:454-8.

**9.1.6 Perioperative Komplikationen****9.1.6.1 Pregabalin bei Postthorakotomiesyndrom**

Metin SK, Meydan B, Evman S, et al. The Effect of Pregabalin and Methylcobalamin combination on the Chronic Postthoracotomy Pain Syndrome, *Ann Thorac Surg* 2017;103:1109-13.

**9.1.6.2 Zeitpunkt der Blasenkatherentfernung postoperative: Früh versus spät?**

Allen MS, Blackmon SH, Nichols FC, et al. Optimal Timing of Urinary Catheter Removal after Thoracic Operations: A Randomized Controlled Study, *Ann Thorac Surg* 2016;102:925-30.

**9.1.7 Kleinzelliges Lungenkarzinom****9.1.7.1 Operation versus Chemotherapie und Strahlentherapie bei frühen oder lokal fortgeschrittenen kleinzelligen Lungenkarzinomen**

Wakeam E, Acuna SA, Leigh NB, et al. Surgery versus Chemotherapy and Radiotherapy for early and locally advanced small cell lung Cancer: A Propensity-matched Analysis of Survival, *Lung Cancer* 109 2017 78-88.

**9.1.7.2 Indikation zur adjuvanten Mediastinalbestrahlung nach operierten kleinzelligen Lungenkarzinomen**

Wakeam E, Giuliani M, Leigh NB, et al. Indications for Adjuvant mediastinal Radiotherapy in Surgically Resected Small Cell lung Cancer, *Ann Thorac Surg* 2017;103:1647-53.

**9.1.7.3 Prophylaktische Hirnbestrahlung bei operierten kleinzelligen Lungenkarzinomen**

Xu J, Yang H, Fu X, et al. Prophylactic Cranial Irradiation for Patients with Surgically resected Small Cell Lung Cancer, *J Thorac Oncol*. Vol 12 No.2:347-353.

**9.2. Mesotheliom****9.2.1 Neue TNM-Klassifikation für das Pleuramesotheliom**

Nowak, AK, Chansky K, Rice DC, et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma, *J Thorac Oncol* Vol 11 No.12:2089-2099.

Rice D, Chansky K, Nowak A, et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural mesothelioma, *J Thorac Oncol* Vol 11 No.12:2100-2111.

Rusch VW, Chansky K, Kindler HL, et al. The IASLC Mesothelioma Staging Project: proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma, *J Thorac Oncol* Vol 11 No.12:2112-2119.

**9.2.2 Einfache versus erweiterte Pleurektomie/Dekortikation bei malignem Pleuramesotheliom**

Marulli G, Breda C, Fontana P, et al. Pleurectomy-decortication in malignant pleural mesothelioma: are different surgical techniques associated with different outcomes? Results from a multicenter study, *Eur J Cardiothorac Surg* 2017;52:63-9.

**9.3 Thymus****9.3.1 Thymektomie bei Myasthenia Gravis – Eine prospektiv randomisierte Untersuchung**

Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized Trial of Thymectomy in Myasthenia Gravis, *N Engl J Med* 2016;375:511-22.

**9.3.2 Sollen Patienten nach Thymomresektion bestrahlt werden?**

Rimner A, Yao X, Huang J, et al. Postoperative Radiation Therapy is associated with longer Overall Survival in Completely Resected Stage II and III Thymoma – An Analysis of the International Thymic Malignancies Interest Group Retrospective Database, *J Thorac Oncol* Vol ■ No. ■: ■-■.

Jackson MW, Palma DA, Camidge DR, et al. The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma, *J Thorac Oncol* Vol 12 No.4;734-744.

**9.4 Lungenmetastasen****9.4.1 Metastasektomie bei Weichteilsarkomen**

Chudgar NP, Brennan MF, Munhoz RR, et al. Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. *J Thorac Cardiovasc Surg* 2017;154:319-30.

**9.4.2 Wachstumsmuster von Lungenmetastasen**

Welter S, Arfanis E, Christoph D, et al. Growth patterns of pulmonary metastases: should we adjust resection techniques to primary histology and size? *Eur J Cardiothorac Surg* 2017;52:39-46.

**9.5 Rundherdmanagement****9.5.1 Intraoperative Rundhermarkierungen durch Elektronavigation**

Abbas A, Kadakia S, Ambur V, et al. Intraoperative electromagnetic navigational bronchoscopic localization of small, deep or subsolid pulmonary nodules, *J Thorac Cardiovasc Surg* 2017;153:1581-90.

Awais O, Reidy MR, Mehta K, et al. Electromagnetic Navigation Bronchoscopy-guided Dye marking for thoracoscopic Resection of Pulmonary Nodules, *Ann Thorac Surg* 2016;102:223-9.

**9.6 Thoraxdrainagenmanagement****9.6.1 Digital versus konventionell**

Miller DL, Helms GA, Mayfield WR, Digital Drainage System Reduces Hospitalization after video-assisted thoracoscopic surgery lung resection, *Ann Thorac Surg* 2016;102:955-61.

**9.6.2 Sog versus Nicht-Sog bei postoperativen Thoraxdrainagen**

Gocyk W, Kuzdzal J, Włodarczyk J, et al. Comparison of Suction versus Nonsuction Drainage after Lung resections: A prospective randomized Trial, *Ann Thorac Surg* 2016;102:1119-24.

**9.7 Pneumothorax****9.7.1 Pneumothorax bei menstruierenden normal großen Frauen**

Metha CK, Stanifer BP, Fore-Kosterski S, et al. Primary Spontaneous Pneumothorax in menstruating women has high recurrence, *Ann Thorac Surg* 2016;102:1125-31.

**9.8 Thoracic-outlet Syndrom (TOS)****9.8.1 Totale endoskopische Resektion der ersten Rippe**

George RS, Milton R, Chaudhuri N, et al. Totally Endoscopic (VATS) first Rib Resection for Thoracic Outlet Syndrome, Ann Thorac Surg 2017;103:241-5.

**9.9 Kongenitale pulmonale Malformationen (CPMs)****9.9.1 Tumorrisiko bei CPMs**

Casagrande A, Pederiva F. Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review, J Thoracic Oncol, Vol.11 No 11: 1837-1845.